1. Home
  2. SAFE vs IVA Comparison

SAFE vs IVA Comparison

Compare SAFE & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Safehold Inc. New

SAFE

Safehold Inc. New

N/A

Current Price

$14.93

Market Cap

1.1B

Sector

Real Estate

ML Signal

N/A

Logo Inventiva S.A. American Depository Shares

IVA

Inventiva S.A. American Depository Shares

N/A

Current Price

$4.70

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SAFE
IVA
Founded
2016
2011
Country
United States
France
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.1B
IPO Year
1999
2020

Fundamental Metrics

Financial Performance
Metric
SAFE
IVA
Price
$14.93
$4.70
Analyst Decision
Hold
Strong Buy
Analyst Count
10
10
Target Price
$19.00
$16.20
AVG Volume (30 Days)
264.1K
699.1K
Earning Date
04-30-2026
03-30-2026
Dividend Yield
4.48%
N/A
EPS Growth
7.43
N/A
EPS
0.82
N/A
Revenue
$385,552,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.31
$751.20
P/E Ratio
$18.60
N/A
Revenue Growth
5.43
N/A
52 Week Low
$12.76
$3.35
52 Week High
$17.45
$7.98

Technical Indicators

Market Signals
Indicator
SAFE
IVA
Relative Strength Index (RSI) 36.79 55.72
Support Level $14.72 $4.11
Resistance Level $15.55 $4.70
Average True Range (ATR) 0.46 0.20
MACD -0.16 -0.01
Stochastic Oscillator 0.00 62.50

Price Performance

Historical Comparison
SAFE
IVA

About SAFE Safehold Inc. New

Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.

Share on Social Networks: